01Mar
24Jan
Researchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant
A novel method for supporting and recovering donor lungs outside the body shows potential to increase the number of organs available for transplant, according to a recent study published in The Journal of Heart and Lung Transplantation. The organ shortage crisis is increasingly dire, as thousands of patients die every year waiting to receive donor organs. Despite urgent demand, nearly 80% of donated lungs are too damaged for transplantation, often due to reversible conditions. A cross-disciplinary team of surgeons and...
06Apr
Xylyx Bio collaboration reveals new insights into tumor drug resistance
Xylyx Bio develops physiologic disease models that enable researchers to gain insights into tumor biology and evaluate the efficacy of drug candidates. Their IN SITE™ Metastasis Kit was recently featured in a publication for a study that showed that dietary interventions may increase the efficacy of treatment for breast cancer metastases. Metastatic breast cancer patients respond poorly to standard of care therapies due, in part, to the failure of conventional models to recreate the complex interactions between tumor cells and...
03Sep
Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute
Xylyx Bio, Inc., a biotechnology company developing groundbreaking solutions for drug discovery and tissue modeling and repair, announced today that it has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF). Read more >>
02Sep
Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery
Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. Read more >>
08Dec
From Conquering COVID-19 to Curing Cancer, New York City Charts the Future of Life Sciences
For the past 25 years, the public and private sectors have worked together to establish New York City as a global leader in life sciences research and innovation. Thanks to that coordinated effort, the city was able to respond to COVID-19 efficiently and effectively, becoming a model for other urban areas as COVID-19 cases peaked across the U.S.—and showcasing a burgeoning life sciences industry in the city that’s poised for future growth... New York life sciences companies continue to step...
30Sep
XYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery
Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Read more >>
16Sep
Patient-Derived Organoids Transform Precision Medicine
Advances in cell culture techniques don’t just mean more accurate models, but more personal ones. For decades scientists have been trying to figure out how to grow cells, especially diseased ones, directly from patients, not only to better understand the mechanisms at play, but also to determine the best approach to cure or correct the malfunction. Today, scientists can grow human tumors in a variety of designer mice, some with human immune systems. Read more >>
27Aug
XYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery
New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Read more >>
21Aug